[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 795 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 795
To prohibit the Department of Health and Human Services from treating
pregnancy as an illness for purposes of approving abortion drugs.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 28, 2025
Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of West
Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Harris of
Maryland, and Mr. Weber of Texas) introduced the following bill; which
was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To prohibit the Department of Health and Human Services from treating
pregnancy as an illness for purposes of approving abortion drugs.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Pregnancy Is Not an Illness Act of
2025''.
SEC. 2. PROHIBITION AGAINST TREATING PREGNANCY AS ILLNESS FOR PURPOSES
OF APPROVING ABORTION DRUGS.
(a) Prohibition.--The Department of Health and Human Services,
including the Food and Drug Administration, shall not treat pregnancy
as an illness for purposes of--
(1) approving any abortion drug under section 505 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355); or
(2) imposing or maintaining any risk evaluation and
mitigation strategy for an abortion drug under section 505-1 of
such Act (21 U.S.C. 355-1).
(b) Nullification of Approvals in Effect.--
(1) In general.--Any prohibited approval of an abortion
drug is hereby nullified.
(2) Prohibited approval defined.--In this subsection, the
term ``prohibited approval of an abortion drug''--
(A) means any approval of an abortion drug under
section 505 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355) that relied in whole or in part on the
treatment of pregnancy as illness; and
(B) includes the approval of mifepristone in effect
under such section 505 on the day before the date of
enactment of this Act.
<all>